These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 30700531

  • 1. mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.
    Nguyen LH, Mahadeo T, Bordey A.
    J Neurosci; 2019 Apr 03; 39(14):2762-2773. PubMed ID: 30700531
    [Abstract] [Full Text] [Related]

  • 2. Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations.
    Wong M.
    Exp Neurol; 2013 Jun 03; 244():22-6. PubMed ID: 22015915
    [Abstract] [Full Text] [Related]

  • 3. Pathogenic MTOR somatic variant causing focal cortical dysplasia drives hyperexcitability via overactivation of neuronal GluN2C N-methyl-D-aspartate receptors.
    Pineau L, Buhler E, Tarhini S, Bauer S, Crepel V, Watrin F, Cardoso C, Represa A, Szepetowski P, Burnashev N.
    Epilepsia; 2024 Jul 03; 65(7):2111-2126. PubMed ID: 38717560
    [Abstract] [Full Text] [Related]

  • 4. Upregulation of the pathogenic transcription factor SPI1/PU.1 in tuberous sclerosis complex and focal cortical dysplasia by oxidative stress.
    Zimmer TS, Korotkov A, Zwakenberg S, Jansen FE, Zwartkruis FJT, Rensing NR, Wong M, Mühlebner A, van Vliet EA, Aronica E, Mills JD.
    Brain Pathol; 2021 Sep 03; 31(5):e12949. PubMed ID: 33786950
    [Abstract] [Full Text] [Related]

  • 5. mTOR-dependent abnormalities in autophagy characterize human malformations of cortical development: evidence from focal cortical dysplasia and tuberous sclerosis.
    Yasin SA, Ali AM, Tata M, Picker SR, Anderson GW, Latimer-Bowman E, Nicholson SL, Harkness W, Cross JH, Paine SM, Jacques TS.
    Acta Neuropathol; 2013 Aug 03; 126(2):207-18. PubMed ID: 23728790
    [Abstract] [Full Text] [Related]

  • 6. Downregulation of CD47 and CD200 in patients with focal cortical dysplasia type IIb and tuberous sclerosis complex.
    Sun FJ, Zhang CQ, Chen X, Wei YJ, Li S, Liu SY, Zang ZL, He JJ, Guo W, Yang H.
    J Neuroinflammation; 2016 Apr 19; 13(1):85. PubMed ID: 27095555
    [Abstract] [Full Text] [Related]

  • 7. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
    Feliciano DM, Lin TV, Hartman NW, Bartley CM, Kubera C, Hsieh L, Lafourcade C, O'Keefe RA, Bordey A.
    Int J Dev Neurosci; 2013 Nov 19; 31(7):667-78. PubMed ID: 23485365
    [Abstract] [Full Text] [Related]

  • 8. mTOR pathway activation in focal cortical dysplasia.
    Kumari K, Sharma MC, Kakkar A, Malgulwar PB, Pathak P, Suri V, Sarkar C, Chandra SP, Faruq M.
    Ann Diagn Pathol; 2020 Jun 19; 46():151523. PubMed ID: 32325422
    [Abstract] [Full Text] [Related]

  • 9. Cell injury and premature neurodegeneration in focal malformations of cortical development.
    Iyer A, Prabowo A, Anink J, Spliet WG, van Rijen PC, Aronica E.
    Brain Pathol; 2014 Jan 19; 24(1):1-17. PubMed ID: 23586324
    [Abstract] [Full Text] [Related]

  • 10. New insights into a spectrum of developmental malformations related to mTOR dysregulations: challenges and perspectives.
    Mühlebner A, Bongaarts A, Sarnat HB, Scholl T, Aronica E.
    J Anat; 2019 Sep 19; 235(3):521-542. PubMed ID: 30901081
    [Abstract] [Full Text] [Related]

  • 11. Hypervascularization in mTOR-dependent focal and global cortical malformations displays differential rapamycin sensitivity.
    Zhang L, Huang T, Teaw S, Bordey A.
    Epilepsia; 2019 Jun 19; 60(6):1255-1265. PubMed ID: 31125447
    [Abstract] [Full Text] [Related]

  • 12. Impaired oligodendroglial turnover is associated with myelin pathology in focal cortical dysplasia and tuberous sclerosis complex.
    Scholl T, Mühlebner A, Ricken G, Gruber V, Fabing A, Samueli S, Gröppel G, Dorfer C, Czech T, Hainfellner JA, Prabowo AS, Reinten RJ, Hoogendijk L, Anink JJ, Aronica E, Feucht M.
    Brain Pathol; 2017 Nov 19; 27(6):770-780. PubMed ID: 27750396
    [Abstract] [Full Text] [Related]

  • 13. Chronic activation of anti-oxidant pathways and iron accumulation in epileptogenic malformations.
    Zimmer TS, Ciriminna G, Arena A, Anink JJ, Korotkov A, Jansen FE, van Hecke W, Spliet WG, van Rijen PC, Baayen JC, Idema S, Rensing NR, Wong M, Mills JD, van Vliet EA, Aronica E.
    Neuropathol Appl Neurobiol; 2020 Oct 19; 46(6):546-563. PubMed ID: 31869431
    [Abstract] [Full Text] [Related]

  • 14. Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia.
    Talos DM, Sun H, Kosaras B, Joseph A, Folkerth RD, Poduri A, Madsen JR, Black PM, Jensen FE.
    Ann Neurol; 2012 Apr 19; 71(4):539-51. PubMed ID: 22447678
    [Abstract] [Full Text] [Related]

  • 15. Oxidative stress and inflammation in a spectrum of epileptogenic cortical malformations: molecular insights into their interdependence.
    Arena A, Zimmer TS, van Scheppingen J, Korotkov A, Anink JJ, Mühlebner A, Jansen FE, van Hecke W, Spliet WG, van Rijen PC, Vezzani A, Baayen JC, Idema S, Iyer AM, Perluigi M, Mills JD, van Vliet EA, Aronica E.
    Brain Pathol; 2019 May 19; 29(3):351-365. PubMed ID: 30303592
    [Abstract] [Full Text] [Related]

  • 16. Activation of leukocyte immunoglobulin-like receptor B2 signaling pathway in cortical lesions of pediatric patients with focal cortical dysplasia type IIb and tuberous sclerosis complex.
    Yue J, Zhang C, Shi X, Wei Y, Liu L, Liu S, Yang H.
    Brain Dev; 2019 Nov 19; 41(10):829-838. PubMed ID: 31495513
    [Abstract] [Full Text] [Related]

  • 17. Activation of extracellular regulated kinase and mechanistic target of rapamycin pathway in focal cortical dysplasia.
    Patil VV, Guzman M, Carter AN, Rathore G, Yoshor D, Curry D, Wilfong A, Agadi S, Swann JW, Adesina AM, Bhattacharjee MB, Anderson AE.
    Neuropathology; 2016 Apr 19; 36(2):146-56. PubMed ID: 26381727
    [Abstract] [Full Text] [Related]

  • 18. Altered expression of the Plexin-B2 system in tuberous sclerosis complex and focal cortical dysplasia IIb lesions.
    Dai L, Huang J, Shen KF, Yang XL, Zhu G, Zhang L, Wang ZK, Liu SY, Liao X, Xu SL, Yang H, Li XY, Zhang CQ.
    Histol Histopathol; 2024 Sep 19; 39(9):1179-1195. PubMed ID: 38293776
    [Abstract] [Full Text] [Related]

  • 19. Focal malformations of cortical development: new vistas for molecular pathogenesis.
    Lim KC, Crino PB.
    Neuroscience; 2013 Nov 12; 252():262-76. PubMed ID: 23892008
    [Abstract] [Full Text] [Related]

  • 20. mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia.
    Nguyen LH, Brewster AL, Clark ME, Regnier-Golanov A, Sunnen CN, Patil VV, D'Arcangelo G, Anderson AE.
    Epilepsia; 2015 Apr 12; 56(4):636-46. PubMed ID: 25752454
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.